Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year Low – Here’s What Happened

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $14.10 and last traded at $14.18, with a volume of 288286 shares traded. The stock had previously closed at $14.73.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. B. Riley reaffirmed a “buy” rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $41.44.

Arrowhead Pharmaceuticals Stock Performance

The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -2.67 and a beta of 0.92. The stock’s 50-day simple moving average is $18.24 and its 200 day simple moving average is $19.68. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Christopher Richard Anzalone sold 11,520 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total transaction of $219,456.00. Following the transaction, the chief executive officer now directly owns 3,764,252 shares in the company, valued at approximately $71,709,000.60. This represents a 0.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the sale, the insider now directly owns 272,122 shares of the company’s stock, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 286,317 shares of company stock worth $5,049,735. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. World Investment Advisors LLC increased its position in Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 700 shares during the period. Xponance Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 4.5% in the 4th quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company’s stock valued at $327,000 after purchasing an additional 744 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Arrowhead Pharmaceuticals by 2.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company’s stock worth $714,000 after buying an additional 803 shares during the period. Wellington Management Group LLP raised its stake in shares of Arrowhead Pharmaceuticals by 1.5% during the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock worth $1,199,000 after buying an additional 886 shares during the last quarter. Finally, ADAR1 Capital Management LLC lifted its holdings in Arrowhead Pharmaceuticals by 10.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 1,195 shares during the period. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.